Showing 1214 results
- Media Release /Solides Wachstum (kWk) beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie[2] im Gesamtjahr Der Nettoumsatz steigt um 5% (kWk), das operative Kernergebnis wächst um 10% (kWk) Die…
- Media Release /Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…
- Media Release /Agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment…
- Media Release /The Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
- Media Release /Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
- Media Release /Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…
- Media Release /Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes…
- Media Release /55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on…
- Media Release /PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met…
- Media Release /Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…